Investment
Features
FeesSafety
Academy
More
Pluang+

Elanco to report Q3 2026 earnings on Nov 6 with live webcast and conference call.

Company Fundamentals
11 Sep 2026
PRNewsWire
View Source
Neutral
Elanco to report Q3 2026 earnings on Nov 6 with live webcast and conference call.

Elanco Animal Health will announce its third quarter 2026 financial results on November 6, 2026. The company will hold a conference call at 8:00 a.m. Eastern Time to discuss its performance, accessible via a live webcast on Elanco's investor website. A replay of the call will be available afterward. This event is important for investors and stakeholders to assess Elanco's recent business progress and outlook.

More News

Medical Informatics Corp. opens Sickbay Demo Center at Texas Medical Center to enhance patient care with real-time data integration.

Medical Informatics Corp. opens Sickbay Demo Center at Texas Medical Center to enhance patient care with real-time data integration.

Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...

Others
Bullish
1 hour ago
Grupo Aeroportuario del Pacífico Q3 earnings miss estimates despite revenue and EBITDA growth.

Grupo Aeroportuario del Pacífico Q3 earnings miss estimates despite revenue and EBITDA growth.

Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...

Company Fundamentals
Neutral
2 hours ago
Northern Trust Q3 2026 earnings expected to rise on higher interest and fee income.

Northern Trust Q3 2026 earnings expected to rise on higher interest and fee income.

Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...

Company Fundamentals
Bullish
2 hours ago
Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
3 hours ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App